MedTrace Logo

A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)

NCT00145002 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2016-09-22

No results posted yet for this study

Summary

To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.

Conditions

Interventions

DRUG

VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis

DRUG

biweekly-CHOP with G-CSF and intrathecal prophylaxis

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • Japan Clinical Oncology Group

    lead OTHER

Principal Investigators

  • Masao Tomonaga, MD, PhD · Nagasaki University Graduate School of Biomedical Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31
Completion
2004-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00145002 on ClinicalTrials.gov